All In Biotech

Drug Trial Radar · NCT01638000

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.

A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy

Last checked: Nov 19, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,887 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,887

Actual

Start

Jun 12, 2012

Primary completion

Apr 24, 2013

Study completion Apr 24, 2013

Sponsor

Lead sponsor
Astellas Pharma Europe Ltd.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jul 11, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of efficacy.

Conditions

  • Urologic Diseases
  • Urinary Bladder, Overactive
  • Urinary Bladder Diseases

Interventions

  • MirabegronDrug

    oral tablet

  • Solifenacin succinateDrug

    oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 HoursTime frame: Baseline and final visit (up to Week 12)

Locations

217 sites in 33 countries. Site status is shown where the registry gives one.

  • Site: 37406

    Yerevan, Armenia

  • Site: 37404

    Yerevan, Armenia

  • Site: 37403

    Yerevan, Armenia

  • Site: 37401

    Yerevan, Armenia

  • Site: 37402

    Yerevan, Armenia

  • Site: 43006

    Baden, Austria

  • Site: 43014

    Graz, Austria

  • Site: 43015

    Innsbruck, Austria

  • Site: 43013

    Linz, Austria

  • Site: 43005

    Oberwart, Austria

  • Site: 43011

    Vienna, Austria

  • Site: 43002

    Vienna, Austria

  • Site: 43003

    Wels, Austria

  • Site: 37502

    Minsk, Belarus

  • Site: 37501

    Minsk, Belarus

  • Site: 37504

    Vitebsk, Belarus

  • Site: 32006

    Brussels, Belgium

  • Site: 32008

    Deurne, Belgium

  • Site: 32001

    Edegem, Belgium

  • Site: 32004

    Ghent, Belgium

  • Site: 32007

    Leuven, Belgium

  • Site: 32005

    Liège, Belgium

  • Site: 35902

    Burgas, Bulgaria

  • Site: 35909

    Haskovo, Bulgaria

  • Site: 35901

    Lovech, Bulgaria

  • Site: 35905

    Plovdiv, Bulgaria

  • Site: 35906

    Sofia, Bulgaria

  • Site: 35908

    Sofia, Bulgaria

  • Site: 35903

    Sofia, Bulgaria

  • Site: 10010

    Abbotsford British Columbia, Canada

  • Site: 10011

    Barrie, Canada

  • Site: 10001

    Bathurst, Canada

  • Site: 10003

    Brampton, Canada

  • Site: 10005

    Brantford, Canada

  • Site: 10007

    Kingston, Canada

  • Site: 10002

    Montreal, Canada

  • Site: 10009

    Sherbrooke, Canada

  • Site: 10004

    Toronto, Canada

  • Site: 10008

    Victoria, Canada

  • Site: 42004

    Bohumín, Czechia

Showing 40 of 217 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.